There are 2949 resources available
1057P - Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing
Presenter: Benjamin Markman
Session: E-Poster Display
Resources:
Abstract
1058P - A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC)
Presenter: Guoqing Zhang
Session: E-Poster Display
Resources:
Abstract
1059P - NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: E-Poster Display
Resources:
Abstract
1060P - HER2-XPAT, a novel protease-activatable pro-drug T-cell engager (TCE), engineered to address on-target, off tumour toxicity and provide large predicted safety margins in non-human primate (NHP)
Presenter: Fiore Cattaruzza
Session: E-Poster Display
Resources:
Abstract
1061P - TCR and HLA analysis of patients in a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)
Presenter: David Anderson
Session: E-Poster Display
Resources:
Abstract
1062P - EGFR-XPAT, a novel pro-drug T-cell engager (TCEs) engineered to address on-target, off-tumour toxicity and an orthogonal approach for cancer immunotherapy in EGFR, KRAS/BRAF cancers
Presenter: Bryan Irving
Session: E-Poster Display
Resources:
Abstract
1063P - Profiling of peripheral T cell receptor beta chain repertoire in non-small cell lung cancer (NSCLC) patients treated with anti-PD1
Presenter: Ning Dong
Session: E-Poster Display
Resources:
Abstract
1064P - Efficacy of a novel anti-CEACAM1 monoclonal antibody and CEACAM1 up-regulation in tumour-infiltrating lymphocytes (TILs) of cancer patients
Presenter: Hyun Jung Cho
Session: E-Poster Display
Resources:
Abstract
1065P - Adverse events reporting in phase III oncology clinical trials of checkpoint inhibitors: A systematic review
Presenter: Marie-Liesse Joulia
Session: E-Poster Display
Resources:
Abstract
1066P - Thyroid toxicity as predictor of response to immunotherapy in lung cancer
Presenter: Vanesa Kazanietz
Session: E-Poster Display
Resources:
Abstract